New CSC Research Finds Nearly 60% of Enterprises Use Three+ SSL Providers, Complicating Digital Certificate Life Cycle Management and Increasing Risk
CSC, an enterprise-class domain security provider and world leader in domain management, DNS, digital certificate management, brand protection, and anti-fraud solutions, today released its inaugural report. “The SSL Landscape” finds that approximately 60% of businesses use three or more secure sockets layer (SSL) providers and suggests a lack of centralized processes for SSL management. This and other evidence further suggest organizations are ignoring or delaying the implementation of a strategic response to the upcoming shortening of SSL certificate life cycles and domain control validation (DCV) re-use periods, opening them up to multiple points of risk.
CSC’s “The SSL Landscape”provides an in-depth analysis on use trends and patterns for more than 802,000 digital certificates linked to 2.4 million domains, including how organizations oversee SSL certificates and the impact on integrity assurance for their domains. The research comes at a key time when SSL/transport layer security (TLS) certificate life cycles are set to shrink from 367 days to 200 starting in 2026 to just 47 by 2029, and DCV re-use periods will decline from 367 days to only 10 by 2028, as mandated by the CA/Browser Forum. Therefore, organizations must update their strategies for renewing certificates nearly eight times a year instead of roughly once a year.
“SSL certificates play a critical role in authenticating the legitimacy and safety of an online brand, including the validation of credentials and the encryption of the connection between a website’s server and a user’s browser,” says Mark Flegg, senior director of technology, CSC Security Products and Services. “As the industry approaches shortened SSL certificate renewal life cycles, organizations cannot afford to delay their transitions to certificate automation or to compromise the security of their organizations with fragmented SSL management. It’s concerning that 72% of respondents we surveyed were either completely unaware of or didn’t know the details of the upcoming industry changes—and as many are unsure of or not ready for automation. Missed renewals could further bring down entire domains and applications that are the backbone of business operations—such as payment gateways, email, VPN, and collaboration tools for chat, video calls, and document sharing.”
According to CSC's research, domain validated (DV) certificates account for three-quarters (73.5%) of certificates while organization validation (OV) certificates represent nearly one-quarter (24.6%) and extended validation (EV) certificates account for less than two percent (1.9%). With low-cost, easy-to-obtain DV certificates dominating the market among organizations, cybercriminals leverage this trend by obtaining similar low-cost certificates to impersonate brands—making fraudulent websites look authentic with a https-secured site—tricking customers into clicking malicious links that compromise data. This research raises concerns about whether IT and security departments have a clear strategy on which certificate is obtained for each type of web asset.
CSC’s findings additionally show that the top three certificate providers are not enterprise-class providers, yet these providers supply the majority of DV certificates (89%) used by the analyzed organizations. The combination of easy-to-obtain certificates and consumer-grade providers who don’t offer the enterprise-class support needed to help companies prepare for upcoming SSL industry changes creates a recipe for serious disruption to organization services and reputation.
“Organizations are about to face the most transformative period for domain security,” continues Flegg. “A lack of understanding around proper certificate strategy, and the absence of urgency to effectively prepare for new certificate life cycles, will leave many online brands and digital identities playing a never-ending game of catch up. Those who prioritize automation, consolidating their certificate solutions providers, and working with enterprise-class domain partners will ensure a smoother, safer transition that minimizes the risk of costly expiration outages and security incidents.”
For more information on key trends in SSL management, download “The SSL Landscape.” To learn more about CSC’s flexible suite of digital certificate management solutions, request a consultation at cscdbs.com.
About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSecSM platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—a combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions.
Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007520413/en/
Contacts
For more information:
Joyson Cherian
W2 Communications
CSC@w2comm.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54332543&newsitemid=20251007520413&lan=en-US&anc
hor=CSC+News+Room&index=6&md5=103dd9509e93688e5bd413889dcc42cd
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom